Last reviewed · How we verify

Osteoarthritis of the hip — Treatment Landscape & Competitive Intelligence

Osteoarthritis of the hip (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteoarthritis of the hip, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Intra-articular corticosteroid injections intra-articular-corticosteroid-injections Pfizer Corticosteroid Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Osteoarthritis of the hip

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteoarthritis of the hip:

Cite this brief

Drug Landscape (2026). Osteoarthritis of the hip — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteoarthritis-of-the-hip. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing